Weekly Recap: RBC $109 target and Mirum’s zilurgisertib milestone royalties
Incyte Corporation (NASDAQ:INCY) faces a mixed outlook as RBC keeps Sector Perform with a $109 target while the company readies U.S. launch of Atebrioz in October, gains a Rare Pediatric Disease priority review voucher, may earn royalties from Mirum’s zilurgisertib, and readies inflammation data fo…